
Investors & Media
Investors & Media
- Overview
- News Releases
- Events & Presentations
- Stock Information
- Corporate Governance
- Financial Information
- Investor Resources
Stockholder Tools
News Releases
News Releases
June 28, 2022
MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to Untreated Randomized Control
May 12, 2022
MeiraGTx Reports First Quarter 2022 Financial and Operational Results
May 4, 2022
MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting
April 27, 2022
MeiraGTx Appoints Debra Yu, MD to Board of Directors
April 19, 2022
MeiraGTx to Participate in Upcoming Investor and Scientific Conferences
March 10, 2022
MeiraGTx Reports Fourth Quarter and Full Year 2021 Financial and Operational Results
January 27, 2022
MeiraGTx Receives Clinical Development Milestone Payment from Janssen
Displaying 11 - 17 of 17
Investors & Media
- Overview
- News Releases
- Events & Presentations
- Stock Information
- Corporate Governance
- Financial Information
- Investor Resources